Trial Profile

A phase IB, open label, single center, drug-drug interaction study of oral 1250 mg of PTK787/ZK 222584 [vatalanib] administered under fasting and fed conditions with a proton-pump inhibitor (omeprazole) in healthy sterile or postmenopausal female volunteers.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 01 Oct 2009

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vatalanib (Primary) ; Omeprazole
Indications Age-related macular degeneration; Colorectal cancer; Gastro-oesophageal reflux; Glioblastoma; Multiple myeloma; Non-small cell lung cancer; Ovarian cancer; Renal cancer; Solid tumours
Focus Pharmacokinetics
Sponsors Novartis

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com